[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Consensus Statement
May 17, 2000

Pulmonary Artery Catheterization and Clinical Outcomes: National Heart, Lung, and Blood Institute and Food and Drug Administration Workshop Report

Author Affiliations

Author Affiliations: Vanderbilt University, Nashville, Tenn (Dr Bernard); National Heart, Lung, and Blood Institute, Bethesda, Md (Drs Sopko and Weinmann and Ms Webb); University of Minnesota, Minneapolis (Dr Cerra); Brigham and Women's Hospital, Boston, Mass (Dr Demling); University of Pennsylvania, Philadelphia (Dr Edmunds); University of California, Los Angeles (Dr Kaplan); Food and Drug Administration, Rockville, Md (Dr Kessler); National Institutes of Health, Bethesda (Dr Masur); University of Colorado, Denver (Dr Parsons); Washington University, St Louis, Mo (Dr Shure); Cleveland Clinic, Cleveland, Ohio (Dr Wiedemann); and Brown University, Providence, RI (Dr Williams). Workshop participants are listed at the end of this article.

JAMA. 2000;283(19):2568-2572. doi:10.1001/jama.283.19.2568

Objective The efficacy and safety of the pulmonary artery catheter are under scrutiny because of its association with increased morbidity and mortality in observational studies. In response, the National Heart, Lung, and Blood Institute (NHLBI) and the US Food and Drug Administration (FDA) conducted the Pulmonary Artery Catheterization and Clinical Outcomes workshop in Alexandria, Va, on August 25 and 26, 1997, to develop recommendations regarding actions to improve pulmonary artery catheter utility and safety.

Participants The NHLBI and FDA planning task force selected a workshop chairperson, subcommittee chairs, and participants. Approximately 85 participants were selected for their collective expertise in critical care, pulmonary medicine, cardiovascular medicine and surgery, pediatrics, nursing, biostatistics, and medical economics. The meeting was open to industry representatives and other government and lay observers. This workshop was funded by the NHLBI and the FDA's Division of Devices.

Evidence Published reports relating to the efficacy and safety of the pulmonary artery catheter, especially consensus documents developed by professional societies.

Consensus Process The planning task force disseminated materials, held teleconferences, and developed draft position papers prior to the workshop. These were modified during the workshop and thereafter in the course of several teleconferences, and presented to the entire group for final modifications and approval.

Conclusions A need exists for collaborative education of physicians and nurses in performing, obtaining, and interpreting information from the use of pulmonary artery catheters. This effort should be led by professional societies, in collaboration with federal agencies, with the purpose of developing and disseminating standardized educational programs. Areas given high priority for clinical trials were pulmonary artery catheter use in persistent/refractory congestive heart failure, acute respiratory distress syndrome, severe sepsis and septic shock, and low-risk coronary artery bypass graft surgery.